Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-05-02 | Spago Nanomedical | Spago Nanomedical interim report January-March 2024 | Rapporter | Ladda ner | Visa Stäng |
Rapporter |
Spago Nanomedical interim report January-March 2024Positive start to an important year JANUARY – MARCH IN BRIEF
SIGNIFICANT EVENTS DURING THE QUARTER
SIGNIFICANT EVENTS AFTER THE QUARTER
CEO STATEMENT Our ongoing phase I/IIa clinical study Tumorad-01 is a first-in-human study with the primary aim of evaluating safety, tolerability, dosimetry and initial effect of 177Lu-SN201 in cancer patients with the aim of identifying a possible therapeutic dose for further studies. In January, we announced that the first patient was successfully treated with the initial dose and the study has since continued as planned. The phase I part of the study aims to, based on safety and biodistribution, identify a possible therapeutic dose for further testing in selected patient groups in the phase IIa part. Based on preclinical results, we assess that there is a good chance of a favorable benefit-risk profile in humans. Using different methods to measure radioactivity in the body, even at low doses, we expect to be able to get an early idea of the possibilities for therapeutic usefulness in cancer patients. Patient recruitment continues and our ambition is to further update the market regarding the study before mid-year. In parallel with the clinical study, an extensive non-clinical program is also underway to explore Tumorad as both a monotherapy and combination therapy in triple-negative breast cancer, a very aggressive and difficult-to-treat form of cancer in which the tumor cells often have resistance to chemotherapy even before the chemotherapy treatment has begun and which makes up approximately 15 percent of all breast cancer cases. It was therefore very gratifying that in April, after the end of the period, we were able to report favorable data from the initial non-clinical study with 177Lu-SN201 as monotherapy showing superior tumor inhibitory effect compared to drugs used in standard treatment with only a low and acceptable level of radiotoxicity being observed. The findings we have seen in this model are very promising and support continued non-clinical development, with evaluation of combination therapy as the next step. The interest in the radiopharma area continues to be high among pharmaceutical companies and specialist investors with several completed transactions of significant size. In March, AstraZeneca strengthened its radiopharma portfolio with the acquisition of the US based Fusion Pharmaceuticals, a transaction worth up to $2.4 billion. Another current example is Bristol Myers Squibb which, at the end of last year, acquired RayzeBio and its radiopharma platform for around USD 4.1 billion. We also see continued interest in our second development program, SpagoPix, and especially in endometriosis where at the end of last year we reported positive topline data from the phase IIa clinical study SPAGOPIX-02 with the contrast agent pegfosimer manganese. The study was an open-label proof-of-concept study with the primary objective of evaluating contrast enhancement in patients with endometriosis. Analysis of study data showed that contrast enhancement could be observed in the majority of lesions confirmed by ultrasound, and thus the primary efficacy objective had been met. The results show the potential of pegfosim manganese in medical imaging of endometriosis lesions and enable further evaluation in the next step. The increasing interest in women’s health in general, and endometriosis specifically, was clearly evident during the annual J.P. The Morgan Health Care conference in January that we attended in order to create new contacts. We participated in several productive meetings with possible future partners. Given the progress within both of our development programs, we have seen a need to strengthen the company’s organization and I am very pleased with the recruitment of Birgitta Rembratt Svensson as the new Head of CMC & Supply. Birgitta is an experienced CMC project manager with senior positions at pharmaceutical companies in the commercial phase, and will join Spago Nanomedical’s management team in June. Procurement, planning and execution of production and distribution will become increasingly important to supply our clinical studies with drugs and, in the longer term, prepare for commercial scale. The recruitment to this key position is thus an important part in building a strong team with a focus on later development phases and commercialization. 2024 will be a very important year for Spago Nanomedical with the greatest focus on the clinical study with our leading program Tumorad. I look forward to continuing to update you on our progress and upcoming milestones . Mats Hansen, CEO Spago Nanomedical AB The interim report is available at the Company’s website; https://spagonanomedical.se/investor-relations/#financial-reports |
||||
2024-05-02 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-mars 2024 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical reports favorable data in breast cancer model with Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-24 | Spago Nanomedical | Spago Nanomedical rapporterar gynnsamma data i bröstcancermodell med Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical strengthens management with Head of CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-04-16 | Spago Nanomedical | Spago Nanomedical stärker ledningen med chef för CMC & Supply | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-28 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 28 mar 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-03-27 | Spago | BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding" | Pressreleaser | Visa Stäng |
|
||||
2024-02-09 | Spago | BioStock: 2023 springboard for Spago's radionuclide cancer therapy | Pressreleaser | Visa Stäng |
|
||||
2024-02-08 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Lockande nyhetsagenda | Pressreleaser | Visa Stäng |
|
||||
2024-02-08 | Redeye | Redeye: Spago Nanomedical Q4 Update | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical year-end report January-December, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-02-07 | Spago Nanomedical | Spago Nanomedical bokslutskommuniké januari-december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-25 | Spago Nanomedical | The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-25 | Spago Nanomedical | Företrädesemissionen och den riktade emissionen till vissa garanter i Spago Nanomedical slutregistrerade | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presenterar på Redeyes temadag Fight Cancer den 24 januari | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-18 | Spago Nanomedical | Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-15 | Spago | BioStock: Spago's phase I/IIa cancer trial progressing steadily | Pressreleaser | Visa Stäng |
|
||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-10 | Spago Nanomedical | Spago Nanomedical går vidare till nästa dosnivå i fas I/IIa-studien Tumorad-01 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-03 | Redeye | Redeye: Spago Nanomedical - Update after funding and initiation of Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-20 | Spago | BioStock: Positive data in Spago's phase IIa endometriosis trial | Pressreleaser | Visa Stäng |
|
||||
2023-12-18 | Penser Access by Carnegie | Penser Access by Carnegie: Spago Nanomedical - Uppmuntrande resultat | Pressreleaser | Visa Stäng |
|
||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-15 | Spago Nanomedical | Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-14 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Spago Nanomedical - Carnegie Investment Bank - 14 dec 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-12-14 | Spago | BioStock: First patient dosed in Spago's phase I/IIa trial | Pressreleaser | Visa Stäng |
|
||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical carries out a directed issue of shares to guarantors following the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-13 | Spago Nanomedical | Spago Nanomedical genomför riktad nyemission av aktier till garanter efter den genomförda företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-12 | Spago Nanomedical | Rights issue in Spago Nanomedical partially registered | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-12 | Spago Nanomedical | Företrädesemissionen i Spago Nanomedical delregistrerad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Spago Nanomedical | Första patienten doserad i Spago Nanomedicals kliniska fas I/IIa-studie inom Tumorad®-programmet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-07 | Spago Nanomedical | First patient dosed in Spago Nanomedical's clinical phase I/IIa study within the Tumorad® program | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical announces outcome of the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-27 | Spago Nanomedical | Spago Nanomedical offentliggör utfall i företrädesemissionen | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Spago Nanomedical | Last day of the subscription period in Spago Nanomedical’s rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Spago Nanomedical | Sista dagen i teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Spago Nanomedical | Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-14 | Spago Nanomedical | Valberedning utsedd inför Spago Nanomedicals årsstämma 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Spago Nanomedical | Idag börjar teckningsperioden i Spago Nanomedicals företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-09 | Spago Nanomedical | The subscription period in Spago Nanomedical’s rights issue begins today | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-08 | Penser Access | Penser Access: Betydelsefullt stöd från huvudägare - Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical offentliggör prospekt med anledning av förestående företrädesemission | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-07 | Spago Nanomedical | Spago Nanomedical publishes prospectus in connection with forthcoming rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical interim report January-September 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-03 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Spago Nanomedical | Bulletin from the Extraordinary General Meeting of Spago Nanomedical AB on 31 October 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-31 | Spago Nanomedical | Kommuniké från extra bolagsstämma i Spago Nanomedical AB den 31 oktober 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng |
|
||||
2023-10-30 | Spago | Spago: BioStock: Tumorad's potential in transforming cancer care | Pressreleaser | Visa Stäng |
|
||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical ansöker om utökat patentskydd för Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-24 | Spago Nanomedical | Spago Nanomedical applies for extended patent protection for Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-23 | Spago | BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa | Pressreleaser | Visa Stäng |
|
||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical får klartecken att starta klinisk fas I/IIa-studie med Tumorad® i Australien | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-19 | Spago Nanomedical | Spago Nanomedical receives approval to initiate the clinical phase I/IIa study with Tumorad® in Australia | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-18 | Spago | Spago Nanomedical presenterar på BioStock Life Science Summit den 25 oktober | Pressreleaser | Visa Stäng |
|
||||
2023-10-11 | Penser Access | Penser Access: Intervju med Spago Nanomedical - Erik Penser Bank - 11 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Kallelse till extra bolagsstämma i Spago Nanomedical AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical proposes a fully guaranteed rights issue of units of approximately SEK 30.6 million to advance Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-05 | Spago Nanomedical | Spago Nanomedical föreslår en fullt garanterad företrädesemission av units om cirka 30,6 MSEK för att avancera Tumorad | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-14 | Penser Access | Penser Access: Sticker ut i mängden - Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-08-01 | Redeye | Redeye: Spago Nanomedical Q2 - Milestone almost concluded, continued cost control crucial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-07-31 | Spago Nanomedical | Spago Nanomedical interim report January-June 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-06-29 | Spago | BioStock: Spago Nanomedical's SAB on Tumorad's potential | Pressreleaser | Visa Stäng |
|
||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical uppdaterar om den kliniska fas IIa-studien SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-28 | Spago Nanomedical | Spago Nanomedical updates on the clinical phase IIa study SPAGOPIX-02 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical stärker Tumorad® genom nytt vetenskapligt råd | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-13 | Spago Nanomedical | Spago Nanomedical strengthens Tumorad® by establishment of Scientific Advisory Board | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-30 | Spago | BioStock: Spago Nanomedical's CDO on study submission | Pressreleaser | Visa Stäng |
|
||||
2023-05-30 | Spago | BioStock: Spago Nanomedicals CDO om studieansökan | Pressreleaser | Visa Stäng |
|
||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical has submitted application to start Tumorad® clinical phase I/IIa study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | Spago Nanomedical | Spago Nanomedical har lämnat in ansökan om att starta klinisk fas I/IIa-studie med Tumorad® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-16 | Spago | BioStock: Tumorad clinical start around the corner for Spago Nanomedical | Pressreleaser | Visa Stäng |
|
||||
2023-05-11 | Redeye | Redeye: Spago Nanomedical - Pivotal year ahead | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Spago Nanomedical | Bulletin from the 2023 Annual General Meeting of Spago Nanomedical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-10 | Spago Nanomedical | Kommuniké från årsstämma 2023 i Spago Nanomedical AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Spago Nanomedical | Spago Nanomedical delårsrapport januari-mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | Spago Nanomedical | Spago Nanomedical interim report January-March 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Spago Nanomedical | Presentation of Spago Nanomedical's clinical phase IIa study in endometriosis at the 15th World Congress of Endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-04 | Spago Nanomedical | Presentation av Spago Nanomedicals kliniska fas IIa-studie i endometrios vid 15th World Congress of Endometriosis | Pressreleaser | Ladda ner | Visa Stäng |
|